Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Berciano-Guerrero Miguel-Ángel, Pérez-Ruiz Elisabeth, Soria Ainara, Medina Martínez Javier, Ayala de Miguel Pablo, Muñoz-Couselo Eva, Bellido Lorena, López Castro Rafael, Espinosa Enrique, Gutiérrez Sanz Lourdes, Cerezuela-Fuentes Pablo, García Castaño Almudena, Crespo Guillermo, Puértolas Teresa, Aguado de la Rosa Carlos, Corral Subias Mónica, Campos Balea Begoña, Bujosa Rodríguez Aida, Navarro Pérez Victor, Lecumberri María José, García Arroyo Francisco Ramón, Cunquero Tomás Alberto Jacobo, Mujika Karmele, Fernández Luis Antonio, Villa Guzmán José Carlos, Hernández Berta, Fra Rodríguez Joaquín, Manzano José Luis, Martín Algarra Salvador, Márquez-Rodas Iván
Аннотация
METHODS: The GEM1801 registry includes patients with advanced melanoma in Spain. For this substudy, patients with metastatic melanoma who received chemotherapy after immunotherapy were selected. Baseline characteristics and treatment outcomes were analyzed.
RESULTS: Of the 1316 patients included, with a median time of 4.8 months (range, 0.0-35.8) from the first immunotherapy, 92 received chemotherapy: 12 after adjuvant immunotherapy (cohort A), 45 subsequently to immunotherapy (cohort B), and 35 after receiving bridge therapies (cohort C). The median age was 66 years (range, 35-94), and 55.4% of the patients were male. Most patients had an Eastern Cooperative Oncology Group (ECOG) status of ≤1 (65.2%), whereas only 21.7% had ECOG 2. Among the patients, 54.3% had elevated lactate dehydrogenase levels. Chemotherapy regimens received were taxane/platinum-based therapies (47.8%), dimethyl triazeno imidazol carboxamide (DTIC) (26.1%), fotemustine (17.4%), and other alkylating agents such as temozolomide (8.7%). With a median follow-up of 31.9 months, the objective response rate was 12%, the median progression-free survival was 3.5 months (95% CI, 2.9-4.8), and the median overall survival was 6.1 months (95% CI, 5.3-9.2).
CONCLUSIONS: As in previous studies, patients treated with chemotherapy after immunotherapy failure had poor outcomes, similar to those from pre-immunotherapy era, and should be used when no other options are available.